Cytrellis Secures Health Canada and Saudi Food and Drug Authority Approval for ellacor® with Micro-Coring® Technology
18 mars 2025 08h05 HE
|
Cytrellis Biosystems
Cytrellis Biosystems has received approval to commercialize its groundbreaking ellacor® with Micro-Coring® technology in Canada and Saudi Arabia.
CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY
10 mars 2025 08h30 HE
|
Carmell Corporation
Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX; CTCXW), a bio-aesthetics company (the “Company”, “we”, “our”, or...
Cosmetic Surgery and Procedure Market Size is Projected to Reach USD 419.97 Billion by 2033, Growing at a CAGR of 14.70%: Straits Research
06 mars 2025 09h35 HE
|
Straits Research Private Limited - Garner Insights
New York, United States, March 06, 2025 (GLOBE NEWSWIRE) -- Cosmetic surgery and procedures encompass a variety of medical and aesthetic interventions aimed at enhancing or altering an individual's...
Cytrellis’ Next-Generation ellacor® Optimizes Micro-Coring for Enhanced Patient and Provider Experience
06 mars 2025 08h00 HE
|
Cytrellis Biosystems
Cytrellis' next-generation ellacor® system with Micro-Coring® enhances patient and provider experience. It will be showcased at industry conferences.
INVESTVIEW, INC. ANNOUNCES SETTLEMENT OF OUTSTANDING SEC INQUIRY
21 janv. 2025 08h00 HE
|
Investview, Inc.
HAVERFORD, PA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Investview, Inc. (OTCQB: INVU), operates a diversified financial technology services company offering multiple business units across key sectors....
Carmell Announces Closing of Elevai Skincare Acquisition
16 janv. 2025 08h00 HE
|
Carmell Corporation
Carmell Announces Closing of Elevai Skincare Acquisition
GLP-1 Medications Fuel Growth in Medical Aesthetics, with Weight Loss Accounting for 11% of Non-Surgical Spending in 2024
09 janv. 2025 09h00 HE
|
Guidepoint Qsight
GLP-1 medications drove 13% of non-surgical aesthetic spend in 2024, reshaping the $19.2B industry as medspas see rising revenue and younger patients.
Cytrellis Biosystems launches Updated Next-Generation Skin Removal Treatment ellacor® 2.0, fueled by new leadership and financing
07 janv. 2025 08h15 HE
|
Cytrellis Bioscience
Cytrellis marks new era of growth with the launch of ellacor 2.0, fueled by the completion of new financing and theappointment of Dr. Denise Dajles as CEO.
Carmell Announces Closing of Previously Announced PIPE Investment from Existing and New Investors to Support Commercial Build-out
03 janv. 2025 08h00 HE
|
Carmell Corporation
PITTSBURGH, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today...
Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products
02 janv. 2025 08h00 HE
|
Carmell Corporation
Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products